检索结果-南通市图书馆

117 cases of advanced malignancies treated with recombinant human endostatin plus chemotherapy

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2013年第2期12卷 61-64页

作者： Pingpo Ming Wei Ge Liang Liu yongfa zheng Huilin Xu Center of Oncology Renmin Hospital of Wuhan University

Objective: The aim of this study was to evaluate the recent efficacy and adverse reactions of recombinant human endostatin (Endostar) plus chemotherapy in the treatment of advanced malignancies. Methods: One hundred and seventeen cases of advanced malignancies were diagnosed and confirmed by histopathological examination, patients were treated with Endostar combined with chemotherapeutic drugs with no cross-resistance. Evaluate the efficacy and adverse reactions after finished two cycles of combination therapy. Results: All the 117 cases of patients were evaluated according to relevant standards, and there were 12 cases of complete remission (CR), 30 cases of partial remission (PR), 58 cases of stable disease (SD), 17 cases of progressive disease (PD). The response rate (RR) was 35.8%, disease control rate (DCR) was 85.4%. Conclusion: The protocol of Endostar combined with chemotherapy could improve the quality of life of patients with malignances, it also has the advantage of low toxicity. Considering the time span of the study, the long-term efficacy remains to be observed.

关键词： advanced malignancies recombinant human endostatin (Endostar) targeted therapy chemotherapy

Clinical observation of pemetrexed on advanced non-small-cell lung cancer

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2011年第3期10卷 140-143页

作者： yongfa zheng Wei Ge Ling Zhang Zhenyu Zhao Fangfang Jie Department of Oncology Renmin Hospital of Wuhan University Wuhan 430060 China

Objective： The aim of our study was to observe the efficacy and toxicity of 50 cases of advanced non-small cell lung cancer （NSCLC） patients treated by pemetrexed. Methods： Fifty patients, including 29 females and 21 males, with a median age 62 years （35–82 years）, 13 of whom were treated with pemetrexed only and the left 37 cases were treated with pemetrexed combined with platinum in the Department of Oncology, Renmin Hospital of Wuhan University from June 2006 to March 2009. Single agent regimen： patients received pemetrexed 500 mg/m2 on day 1 with every 21 days. Combination regimen： patients received pemetrexed 500 mg/m2 on day 1 and carboplatin 300 mg/m2 on day 1 or cisplatin 35 mg/m2 on day 1 to day 3 or nedaplatin 80 mg/m2 on day 1 by intravenous infusion with 21 days as one cycle. RECIST 1.0 standard was used to evaluate the clinical efficiency, and the WHO toxicity standard was used to evaluate toxic reaction, and the QOL was used to evaluate the quality of life. Results： All patients were given 162 cycles （at least 2 cycles, at most 6 cycles） and the response rate of all the patients were evaluated. There were 2 complete remission （CR）, 7 partial remission （PR）, 22 stable disease （SD） and 19 progressive disease （PD） in the group, the overall response rate was （RR） was 18.0% and disease control rate （DCR） 62.0%. The quality of life improvement rate reaches 58.0%. The major toxic reaction included neutropenia, thrombocytopenia, hypemia, nausea, and vomiting. Most of the severity of these effects was grade I–II and well tolerated. Conclusion： Chemotherapy with pemetrexed or pemetrexed combined with platinum in the treatment of advanced non-small cell lung cancer is effective, safe and well-tolerable, which can improve quality of life of the patient.

关键词： non-small-cell lung cancer pemetrexed chemotherapy

17 cases of advanced non-small cell lung cancer treated with paclitaxel liposome plus nedaplatin

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2012年第4期11卷 196-198页

作者： Tao Suo Wei Ge Jinzhong Zhang yongfa zheng Shunxiang Luo Department of Oncology Renmin Hospital of Wuhan UniversityWuhan 430060China

Objective： The aim of this study was to evaluate the recent efficacy and adverse reactions of paclitaxel liposome plus nedaplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： Seventeen cases of NSCLC treated with paclitaxel liposome and nedaplatin for 2 to 6 cycles, by infusing paclitaxel liposome 135 mg/m^2 for 3 h on d 1 and nedaplatin 80 mg/m^2 as infusion on d2. Results： Among 17 patients being evaluated for response to treatment, 1 achieved complete response （CR）, 4 achieved partial response （PR）, 3 achieved stable disease （SD）, 9 achieved progress disease （PD）. The main adverse reaction was haematological toxicities, especially leukopenia and thrombocytopenia. The non-hae- matological toxicities included nausea, vomiting, mild hepatic dysfunction, alopecia and so on. Conclusion： Paclitaxel lipo- some plus nedaplatin was effective and well tolerated for treating patients with advanced NSCLCo

关键词： paclitaxel liposome nedaplatin non-small cell lung cancer (NSCLC)

Study of the impact of CT/CT image fusion radiotherapy on V_(20) and radiation pneumonitis of non-small cell lung cancer

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2012年第2期11卷 72-75页

作者： Liang Liu Jinzhong Zhang Changhu Li Wei Ge Shunxiang Luo Yu Huang yongfa zheng Center of Oncology Renmin Hospital of Wuhan UniversityWuhan 430060China

Objective:The aim of our study was to investigate the value of CT/CT image fusion radiation treatment planning in non-small cell lung cancer(NSCLC) and the impact on V20 and radiation pneumonitis(RP).Methods:Patients who were pathologically or cytologically diagnosed of stage IIIA and IIIB NSCLC were treated with three-dimensional conformal radiation therapy(4000 cGy).Forty patients got at least 25% tumor reduction were randomly divided into two groups:group A of regular shrink field radiotherapy(20 cases) and group B of CT/CT image fused shrink field radiotherapy(20 cases).Dosage reached 6600 *** data,V20 and RP were observed within 3 months after *** analysis was conducted for the NSCLC ***:22.5%(9/40) patients got RP during *** A accounted for 6 cases(30%),and group B had 3 cases(15%).There was no marked difference between the two groups(P = 0.256),univariate analysis revealed that the IV20 of A and B groups,and IV20 and CV20 of all patients were statistically related to the incidence of RP(P < 0.05).With Wilcoxon method assay,the ipsilateral lung V20 and contralateral lung V20 had statistical significance between the two groups(P < 0.05).Conclusion:The CT/CT image infusion treatment planning could increase the radical dosage with better tumor control probability but won't increase adverse reaction.

关键词： non-small cell lung cancer three-dimensional conformal radiation therapy radiation pneumonitis CT/CT image fusion V20

Clinical study of docetaxel combined with concurrent radiotherapy in patients with advanced nasopharyngeal carcinoma

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2013年第12期12卷 592-595页

作者： Wei Luo Wei Ge yongfa zheng Xianfeng Pan Jing Song Huilin Xu Pingpo Ming Cancer Center Renmin Hospital of Wuhan University

Objective： The aim of this study was to study the short-term curative effects and adverse reactions of docetaxel （DOC） in concurrent chemoradiotherapy compared to DDP plus 5-Fu （DF） combined with concurrent radiotherapy in patients with advanced nasopharyngeal carcinoma. Methods： Thirty-three patients in the experimental group （DOC group） were given DOC 25 mg/m2 ivgtt, dl, 7 times, concurrent radiotherapy was performed from dl. Thirty-three patients in the control group （DF group） were given cisplatin 25 mg/@ivgtt dl-3 and 5-Fu 550 mg/m2iv, dl-5, 3 weeks a cycle, 2 cycles, and concurrent radiotherapy was performed from dl. Six MV X-ray and 9 MeV electronic line for external irradiation were adopted in concur- rent radiotherapy. Results： The response rates of DOC group and DF group were 90.9% and 93.9%, the rates of neutropenia were 45.45% and 67.74%, and the rates of oral mucositis were 60.61% and 90.32%. Conclusion： The difference of short- term curative effects between DOC group and DF group was not statistically significant in patients with advanced nasopha- ryngeal carcinoma. The rates of adverse reactions were lower in DOC group. DOC combined with concurrent radiotherapy could be a new choice for patients with advanced nasopharyngeal carcinoma.

关键词： nasopharyngeal carcinoma docetaxel (DOC) concurrent radiotherapy

在线全文

学校读者我要写书评

暂无评论

天然抗菌剂茶树油在医用敷料中的应用研究

化工新型材料 2013年第12期41卷 179-180页

作者：陈煜郑永发邵立伟郑永健北京理工大学材料学院北京100081 广东富阳生物科技有限公司河源517000 中山北京理工大学研究院中山528400

结合目前国内外医用敷料领域日益受到重视的新型医用敷料提高抗菌性能的技术需求,介绍了天然抗菌剂茶树油优异的抗菌性能,及其在医用敷料中的应用情况,并对其在大出血止血用高端医用敷料领域的应用趋势进行了介绍。

关键词：茶树油抗菌医用敷料应用

营养状态对肺腺癌患者接受免疫联合化学治疗疗效及不良反应的影响

在线全文

学校读者我要写书评

暂无评论

武汉大学学报（医学版） 2024年第3期45卷 311-315页

作者：包文庭张道明郑永法武汉大学人民医院肿瘤中心湖北武汉430060

目的:探究营养状态对免疫联合化学治疗肺腺癌患者疗效及不良反应的影响。方法:回顾性分析武汉大学人民医院肿瘤中心接受免疫联合化学治疗的肺腺癌患者65例,根据NRS2002将患者分为无营养风险组(A组)和营养风险组(B组)。对比两组的近期疗... 详细信息

目的:探究营养状态对免疫联合化学治疗肺腺癌患者疗效及不良反应的影响。方法:回顾性分析武汉大学人民医院肿瘤中心接受免疫联合化学治疗的肺腺癌患者65例,根据NRS2002将患者分为无营养风险组(A组)和营养风险组(B组)。对比两组的近期疗效、治疗期间的不良反应以及生活质量。结果:纳入患者中,无营养风险组32例,营养风险组33例。A组治疗疗效优于B组(P<0.05),营养状态及体质量指数(BMI)是治疗疗效的显著影响因素。A组患者2级及以上皮肤毒性、胃肠道毒性的发生率明显低于B组患者(P<0.05)。生活质量方面,A组的躯体功能、角色功能、情感功能评分均高于B组(P<0.05)。结论:良好的营养状态有助于减轻接受免疫联合化学治疗肺癌患者的毒副反应,同时有利于改善生活质量,可能是疗效获益的有利因素。

关键词：免疫治疗营养状态生活质量

内皮抑素联合放疗治疗残胃癌术后多处淋巴结转移1例报告

在线全文

学校读者我要写书评

暂无评论

武汉大学学报（医学版） 2011年第2期32卷 265-268页

作者：张令戈伟陈宇邓君健郑永法武汉大学人民医院肿瘤科湖北武汉430060

目的:通过1例残胃癌术后多处淋巴结转移探讨内皮抑素(恩度)联合放疗的近期疗效、毒副反应及耐受性。方法:根据PET-CT指引给予高代谢灶放疗,放疗期间每周一、周三、周五给予内皮抑素15 mg/d。按照RE-CIST标准评价近期疗效,参照PS评分变... 详细信息

目的:通过1例残胃癌术后多处淋巴结转移探讨内皮抑素(恩度)联合放疗的近期疗效、毒副反应及耐受性。方法:根据PET-CT指引给予高代谢灶放疗,放疗期间每周一、周三、周五给予内皮抑素15 mg/d。按照RE-CIST标准评价近期疗效,参照PS评分变化评价生活质量(QOL),按照NCI CTC 3.0版标准评价毒性反应。结果:该例患者治疗后疗效评价为完全缓解,PS评分提高到0分,主要毒副反应为Ⅲ度骨髓抑制。结论:内皮抑素联合放疗治疗残胃癌术后多处淋巴结转移具有良好的近期疗效,可改善患者生活质量,毒性较低,安全性和耐受性好。

关键词：内皮抑素放疗残胃癌

非典型Scheuermann病和颈椎脊髓病

在线全文

学校读者我要写书评

暂无评论

中国中西医结合外科杂志 2006年第4期12卷 339-342页

作者：郑永发王沛天津医科大学总医院骨科天津300052

目的对非典型Scheuermann病所致的颈椎脊髓病的病理、影像和临床特点,与颈椎间盘突出的关系进行比较,以便评价和指导治疗。方法颈椎脊髓病84例中有12例MRI所见确切符合非典型Scheuermann病征。行后路椎板切除减压术10例;2例移位椎间盘... 详细信息

目的对非典型Scheuermann病所致的颈椎脊髓病的病理、影像和临床特点,与颈椎间盘突出的关系进行比较,以便评价和指导治疗。方法颈椎脊髓病84例中有12例MRI所见确切符合非典型Scheuermann病征。行后路椎板切除减压术10例;2例移位椎间盘后方原有片状高信号影者行前路一个节段减压植骨融合术。结果非典型Scheuermann病组和对照组年龄差异有显著意义。X线可显示终板不平整或硬化,椎体形状不规则。MRI可见单一或多个椎间隙的软骨结节,或终板不平整,相应椎体缘显示不规则高信号。结论软骨结节为特征的非典型Scheuermann病是椎骨常见的发育异常,累及椎体的次发骨骺,多合并椎间盘向后移位、突出,是颈椎脊髓病常见的病理类型。

关键词：非典型Scheuermann病颈椎脊髓病软骨结节椎间盘切除术椎板减压术